<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04178070</url>
  </required_header>
  <id_info>
    <org_study_id>GENOR GB224-001; V1.4</org_study_id>
    <nct_id>NCT04178070</nct_id>
  </id_info>
  <brief_title>Phase Ⅰ Clinical Trial of Gerilimzumab Injection in Healthy Subjects</brief_title>
  <official_title>A Randomized, Double-blind, Placebo-controlled, Single Dose, Dose-escalated Phase Ⅰ Clinical Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Gerilimzumab in Healthy Adult Subjects.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Genor Biopharma Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Genor Biopharma Co., Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objectives of this study are to evaluate the safety, tolerability and
      pharmacokinetic (PK) profiles of single-dose, dose-escalated, abdominal subcutaneous
      injection of GB224 in Chinese healthy adult subjects. The secondary objectives are to
      preliminarily understand the immunogenicity and pharmacodynamic variable (IL-6) of single
      abdominal subcutaneous injection of GB224 in Chinese healthy adult subjects.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 6, 2017</start_date>
  <completion_date type="Anticipated">April 2021</completion_date>
  <primary_completion_date type="Anticipated">December 2020</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Adeverse Effect, AE</measure>
    <time_frame>Up to 112 days.</time_frame>
    <description>Adeverse Effect, AE</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Serious Adeverse Effect, AE</measure>
    <time_frame>Up to 112 days.</time_frame>
    <description>Serious Adeverse Effect, AE</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum Tolerated Dose, MTD</measure>
    <time_frame>Up to 112 days.</time_frame>
    <description>Maximum Tolerated Dose, MTD</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Dose Limited Toxicity, DLT</measure>
    <time_frame>Up to 112 days.</time_frame>
    <description>Dose Limited Toxicity, DLT</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>AUC0-t</measure>
    <time_frame>Up to 112 days.</time_frame>
    <description>AUC0-t</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cmax</measure>
    <time_frame>Up to 112 days.</time_frame>
    <description>Cmax</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC0-∞</measure>
    <time_frame>Up to 112 days.</time_frame>
    <description>AUC0-∞</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tmax</measure>
    <time_frame>Up to 112 days.</time_frame>
    <description>Tmax</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vd</measure>
    <time_frame>Up to 112 days.</time_frame>
    <description>Vd</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ke</measure>
    <time_frame>Up to 112 days.</time_frame>
    <description>Ke</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Retention Time, MRT</measure>
    <time_frame>Up to 112 days.</time_frame>
    <description>Mean Retention Time, MRT</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>t1/2</measure>
    <time_frame>Up to 112 days.</time_frame>
    <description>t1/2</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CL</measure>
    <time_frame>Up to 112 days.</time_frame>
    <description>CL</description>
  </secondary_outcome>
  <number_of_arms>12</number_of_arms>
  <enrollment type="Anticipated">58</enrollment>
  <condition>Rheumatoid Arthritis</condition>
  <arm_group>
    <arm_group_label>GB224 2mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>single dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>GB224 5mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>single dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>GB224 10mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>single dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>GB224 15mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>single dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>GB224 20mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>single dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>GB224 30mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>single dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo 2mg</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>single dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo 5mg</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>single dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo 10mg</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>single dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo 15mg</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>single dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo 20mg</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>single dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo 30mg</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>single dose</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>GB224 2mg</intervention_name>
    <description>2mg (100μL), single dose, abdominal subcutaneous injection</description>
    <arm_group_label>GB224 2mg</arm_group_label>
    <other_name>Gerilimzumab injection</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>GB224 5mg</intervention_name>
    <description>5mg (250μL), single dose, abdominal subcutaneous injection</description>
    <arm_group_label>GB224 5mg</arm_group_label>
    <other_name>Gerilimzumab injection</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>GB224 10mg</intervention_name>
    <description>10mg (500μL), single dose, abdominal subcutaneous injection</description>
    <arm_group_label>GB224 10mg</arm_group_label>
    <other_name>Gerilimzumab injection</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>GB224 15mg</intervention_name>
    <description>15mg (750μL), single dose, abdominal subcutaneous injection</description>
    <arm_group_label>GB224 15mg</arm_group_label>
    <other_name>Gerilimzumab injection</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>GB224 20mg</intervention_name>
    <description>20mg (1mL), single dose, abdominal subcutaneous injection</description>
    <arm_group_label>GB224 20mg</arm_group_label>
    <other_name>Gerilimzumab injection</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>GB224 30mg</intervention_name>
    <description>30mg (1.5mL), single dose, abdominal subcutaneous injection</description>
    <arm_group_label>GB224 30mg</arm_group_label>
    <other_name>Gerilimzumab injection</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo, 2mg</intervention_name>
    <description>2mg (100μL), single dose, abdominal subcutaneous injection</description>
    <arm_group_label>Placebo 2mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo, 5mg</intervention_name>
    <description>5mg (250μL), single dose, abdominal subcutaneous injection</description>
    <arm_group_label>Placebo 5mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo, 10mg</intervention_name>
    <description>10mg (500μL), single dose, abdominal subcutaneous injection</description>
    <arm_group_label>Placebo 10mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo, 15mg</intervention_name>
    <description>15mg (750μL), single dose, abdominal subcutaneous injection</description>
    <arm_group_label>Placebo 15mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo, 20mg</intervention_name>
    <description>20mg (1mL), single dose, abdominal subcutaneous injection</description>
    <arm_group_label>Placebo 20mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo, 30mg</intervention_name>
    <description>30mg (1.5mL), single dose, abdominal subcutaneous injection</description>
    <arm_group_label>GB224 30mg</arm_group_label>
    <arm_group_label>Placebo 30mg</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Understand the study procedures and contents, and voluntarily sign the informed
             consent form;

          2. Chinese healthy adult volunteers aged 18 to 45 years, males and females;

          3. The subjects have qualified physical examination within 30 days before the study, the
             body mass index (BMI) is within the range of 19~24 and the body weight is within the
             range of 45~75kg;

          4. Males or females agree to adopt medically confirmed effective contraceptive measures
             during the entire study period and within 6 months after the end of this study.

          5. The investigator considers that the patients have good health condition according to
             the physical examination, medical history, vital signs and ECG etc.

          6. Patients have good compliance, can receive follow-up visits as scheduled, are able to
             well communicate with the investigators and complete the study as required by the
             study.

        Exclusion Criteria:

          1. Any of the following is met: allergic constitution; known allergic to the components
             of the investigational product or allergy history to any drug or food or pollen;
             subjects who have medical history of skin allergy such as physical urticaria; subjects
             who have abnormal serum immunoglobulin E (IgE) test;

          2. Any of the current symptoms, signs or laboratory test abnormalities indicating the
             possible presence of acute or subacute infection (e.g., pyrexia, cough, urgent
             micturition, urodynia, abdominal pain, diarrhea, cutaneous infected wound etc.)

          3. Patients with active pulmonary tuberculosis; patients who previously had medical
             history of active pulmonary tuberculosis;

          4. Subjects who have medical history of drug addiction or drug abuse;

          5. Subjects who have clear medical history of central nervous system, cardiovascular,
             renal, hepatic, gastrointestinal, respiratory, metabolic system or subjects with other
             significant diseases; subjects with medical history of hypertension or screening
             systolic blood pressure ≥ 140mmHg and/or diastolic blood pressure ≥ 90mmHg, which are
             clinically significant at the discretion of the investigators; subjects who have
             medical history of orthostatic hypotension;

          6. Subjects who have medical history of malignant tumors;

          7. Subjects who participated in other clinical studies within 3 months before enrollment,
             or subjects who received drugs which are known to injure the major organs within 3
             months before enrollment;

          8. Subjects who used prescription drugs or non-prescription drugs within 14 days before
             enrollment;

          9. Subjects who have blood donation history within 3 months before enrollment;

         10. Subjects who meet any of the following criteria: alanine aminotransferase (ALT) or
             aspartate aminotransferase (AST) &gt;1.5 times the upper limit of normal (ULN), serum
             creatinine (Cr) &gt; the upper limit of normal (ULN);

         11. Abnormal routine blood tests: any of the following is met: white blood cells
             (WBC)&lt;3.0×109/L or &gt;9.5×109/L, neutrophil count (ANC)&lt;1.5×109/L, platelet count
             (PLT)&lt;100×109/L, hemoglobin (HGB)&lt;104g/L;

         12. Any of the following is positive: hepatitis B surface antigen (HBsAg), hepatitis C
             antibody (HCV-Ab), acquired immunodeficiency syndrome antibody (Anti-HIV) and
             anti-treponema pallidum antibody (TP-Ab);

         13. Subjects who have positive tuberculosis skin test (5 units of dosage, induration of
             not less than 5 millimeters (mm) within 48 ~ 72 hours);

         14. Subjects with positive anti-nuclear antibody (ANA), anti-double stranded DNA antibody
             (ds-DNA) and anti-extractable nuclear antigens (ENA);

         15. Subjects with positive anti-drug antibody (ADA);

         16. Subjects with positive tumor markers (CEA, AFP, PSA and CA-125);

         17. Subjects with abnormal coagulation function, which is clinically significant at the
             discretion of the investigators;

         18. Subjects with medical history of psychiatric disorders;

         19. Smoking more than 5 cigarettes/day or equivalent tobacco;

         20. Weekly alcohol consumption more than 28 units (1 unit = 285 mL of beer or 25 mL of
             spirits or a glass of wine); or subjects who have positive breath alcohol test within
             24 hours before the use of investigational drug;

         21. Subjects who have clinically significant abnormal laboratory test values at screening;

         22. Female subjects who have positive serum/urine pregnancy tests at screening or
             lactating women;

         23. Patients who have insufficient communication, understanding and cooperation; or
             patients who have poor compliance and cannot guarantee to strictly follow the study
             protocol;

         24. Subjects who are considered unsuitable for participating in this study for various
             reasons at the discretion of the investigator.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yi Fang, Ph.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>Peking University People's Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Shawn Yu, Master</last_name>
    <phone>010-65260820</phone>
    <email>Shawn.Yu@genorbio.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Peking University People's Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100191</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yi Fang, Ph.D</last_name>
      <phone>010-66583834</phone>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>November 2019</verification_date>
  <study_first_submitted>November 24, 2019</study_first_submitted>
  <study_first_submitted_qc>November 24, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">November 26, 2019</study_first_posted>
  <last_update_submitted>November 25, 2019</last_update_submitted>
  <last_update_submitted_qc>November 25, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">November 27, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arthritis</mesh_term>
    <mesh_term>Arthritis, Rheumatoid</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

